Sionna Therapeutics Inc
NASDAQ:SION
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Sionna Therapeutics Inc
Net Issuance of Common Stock
Sionna Therapeutics Inc
Net Issuance of Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Sionna Therapeutics Inc
NASDAQ:SION
|
Net Issuance of Common Stock
$205.7m
|
CAGR 3-Years
23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Issuance of Common Stock
-$808m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
20%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Issuance of Common Stock
-$1.5B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
17%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Issuance of Common Stock
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Issuance of Common Stock
-$1.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-47%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Issuance of Common Stock
-$2.8B
|
CAGR 3-Years
-71%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Sionna Therapeutics Inc
Glance View
Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.
See Also
What is Sionna Therapeutics Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
205.7m
USD
Based on the financial report for Dec 31, 2025, Sionna Therapeutics Inc's Net Issuance of Common Stock amounts to 205.7m USD.
What is Sionna Therapeutics Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
23%
Over the last year, the Net Issuance of Common Stock growth was 13%. The average annual Net Issuance of Common Stock growth rates for Sionna Therapeutics Inc have been 23% over the past three years .
